Lenacapavir is a revolutionary long-acting injectable drug that offers six months of protection with just two annual ...

South Africa's Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...

South Africa’s Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

The drug, Lenacapavir, is the world's first injectable Pre-Exposure Prophylaxis (PrEP). According to the World Health ...

The South African Health Products Regulatory Authority has approved Lenacapavir, a long-acting injection that prevents HIV ...

The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa's medicines regulator. The approval helps to clear the way for a limited public sector ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool ...

Through a US$ 29 million grant, South Africa will receive enough medicine to provide HIV prevention to 450 000 people at high ...